Revelation Biosciences (FRA:56U0) Pre-Tax Income : €-8.29 Mil (TTM As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Revelation Biosciences Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Revelation Biosciences's pretax income for the three months ended in Mar. 2024 was €-2.47 Mil. Its pretax income for the trailing twelve months (TTM) ended in Mar. 2024 was €-8.29 Mil. Revelation Biosciences's pretax margin was %.

Revelation Biosciences Pre-Tax Income Historical Data

The historical data trend for Revelation Biosciences's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revelation Biosciences Pre-Tax Income Chart

Revelation Biosciences Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Pre-Tax Income

-10.61

-10.22

-0.11

Revelation Biosciences Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Pre-Tax Income	Get a 7-Day Free Trial								5.75	-1.34	-2.46	-2.02	-2.47

Competitive Comparison of Revelation Biosciences's Pre-Tax Income

For the Biotechnology subindustry, Revelation Biosciences's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Revelation Biosciences's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Revelation Biosciences's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Revelation Biosciences's Pre-Tax Income falls into.

Revelation Biosciences Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Revelation Biosciences's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-7.938	+	7.828	+	0	+	0	+	-5.6898930012039E-16
	=	-0.11

Revelation Biosciences's Pretax Income for the quarter that ended in Mar. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-1.75	+	-0.717	+	0	+	0	+	0
	=	-2.47

Pre-Tax Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-8.29 Mil.

Revelation Biosciences (FRA:56U0) Pre-Tax Income Explanation

Revelation Biosciences's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-2.467	/	0
	=	%

Revelation Biosciences Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Revelation Biosciences's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Revelation Biosciences (FRA:56U0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revelation Biosciences Inc (FRA:56U0) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

REVB:USA 56U1:Germany

Address

4660 La Jolla Village Drive, Suite 100, San Diego, CA, USA, 92122

Website

https://www.revbiosciences.com

Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. It has several product candidates in development. REVTx-99, the lead therapeutic candidate, is an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2, including its variants, influenza A and B, parainfluenza, rhinovirus, and RSV. REVTx-99 is also being developed for other indications such as: allergic rhinitis and chronic nasal congestion. REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx-200 is based on the same technology used in REVTx-99.

Revelation Biosciences (FRA:56U0) Headlines

No Headlines